AZN - AstraZeneca PLC
| Previous Close | 35.40 |
| Open | 35.41 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 35.28 - 35.50 |
| 52 Week Range | 28.43 - 36.75 |
| Volume | 2,488,541 |
| Avg. Volume | 4,328,831 |
| Market Cap | 86.077B |
| Beta | 0.57 |
| PE Ratio (TTM) | 29.82 |
| EPS (TTM) | 1.18 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.92%) |
| Ex-Dividend Date | 2018-02-15 |
| 1y Target Est | 38.89 |
Yahoo Finance Video•5 days agoNEWS BITES: Barbara Bush dies at 92, Sessions proposes new limits on opioid production, tax day extended
Here’s a quick wrap up of other headlines making news today.
- Zacks•3 days ago
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
- Zacks•4 days ago
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.
- Reuters•4 days ago
AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug
U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday. The latest Food and Drug Administration approval includes patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
- Market Realist•5 days ago
Analysts’ Recommendations for Novartis on April 17
Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.
- Market Realist•5 days ago
Novartis’s 1Q18 Estimates: Expectations for Alcon
Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.
- American City Business Journals•5 days ago
A new Highmark contract with a pharma company part of a growing trend in drug purchasing
If a certain drug doesn't work to manufacturers' expectations, then the insurer either doesn't pay for it or gets a rebate.
- Market Realist•6 days ago
Updates on AbbVie’s AndroGel, Lupron, and Kaletra
In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter. In fiscal 2017, AndroGel generated revenue of $577 million, marking a ~14.5% decline YoY.
- Simply Wall St.•6 days ago
An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Shows It’s 34% Undervalued
How far off is AstraZeneca PLC (LSE:AZN) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...
- Business Wire•7 days ago
Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today presented data from the Phase III OlympiAD trial, showing the final overall survival results for LYNPARZA® in metastatic breast cancer at the American Association for Cancer Research Annual Meeting in Chicago, April 14-18, 2018.
- Market Realist•12 days ago
Barclays Downgrades Pfizer Stock and Cuts Price Target
On April 5, 2018, Barclays (BCS) updated its recommendations for some leading US pharmaceutical companies. It downgraded its recommendation for Pfizer (PFE) from “overweight” to “equal weight,” and Barclays analyst Geoff Meacham cut his price target on Pfizer stock from $41 to $38. That day, Pfizer stock fell ~1.3% following the announcement of the rating downgrade.
- Zacks•12 days ago
Spectrum Pharma Stock Up on Positive Lung Cancer Study Data
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
- Market Realist•12 days ago
What Boosted Merck’s Stock Price on April 9
On April 9, 2018, Merck (MRK) stock rose ~4.4% in early trading and ~2.7% during the day. The highest price reached on April 9 was 7% higher than the stock’s April 8 closing price. Peers Bristol-Myers Squibb (BMY), AstraZeneca (AZN), and Roche (ROG) returned -0.08%, 0.24%, and 0.05%, respectively on April 9, and the SPDR S&P 500 ETF (SPY) rose ~1.1%. MRK accounts for ~0.65% of SPY’s total holdings.
- Market Realist•12 days ago
How GlaxoSmithKline Stock Performed in 1Q18
GlaxoSmithKline (GSK) is a British multinational pharmaceutical company with headquarters in Brentford, Middlesex. The company classifies its business portfolio into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
- Zacks•12 days ago
Ionis (IONS) Clinches Licensing Agreement with AstraZeneca
Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.
- Market Realist•13 days ago
How AstraZeneca’s 1Q18 Shook Out
Headquartered in London, AstraZeneca (AZN) is a pharmaceutical company with operations in over 100 countries. The company is involved in the research, development, and manufacture of drugs for both primary care and specialty care.
- Zacks•13 days ago
Top Analyst Reports for Microsoft, Merck & Union Pacific
Top Analyst Reports for Microsoft, Merck & Union Pacific
- Market Realist•13 days ago
Assessing the Performance of Novartis Stock in 1Q18
Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company that specializes in researching, developing, manufacturing, and marketing a broad range of healthcare products.
- Investopedia•14 days ago
DAOs and the Potential of Ownerless Business
DAOs are possibly the most cost effective and fair business model ever conceived.
- MarketWatch•14 days ago
Ionic Pharmaceuticals shares jump 3% premarket on news of license deal with AstraZeneca
Ionis Pharmaceuticals Inc. shares rose 3% premarket Monday, after the company unveiled a licensing deal with AstraZeneca PlC for a treatment for nonalcoholic steatohepatitis (NASH), or fatty liver. Ionis ...
- Reuters•14 days ago
Ionis to get up to $300 mln from licensing deal with AstraZeneca
Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties. ...
- PR Newswire•14 days ago
Ionis and AstraZeneca Advance New Drug for NASH
CARLSBAD, Calif., April 9, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca (AZN) following advancement of the drug into development. In conjunction with this milestone, global, science-led biopharmaceutical company AstraZeneca will pay a $30 million license fee to Ionis. AstraZeneca will be responsible for further development and commercialization of IONIS-AZ6-2.5-LRx.
- Zacks•17 days ago
Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus
Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study
- Market Realist•17 days ago
Understanding FibroGen’s Research Pipeline
FibroGen (FGEN) is capitalizing on its extensive experience in fibrosis and hypoxia-inducible factor (or HIF) biology to advance a pipeline targeted for the treatment of anemia, fibrotic disease, cancer, and corneal blindness. Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200. FG-3019 is a fully human monoclonal antibody that inhibits the activity of connective tissue growth factor.
- Yahoo Finance Contributors•14 days ago
5 Trade Ideas for Monday: AstraZeneca, Bristol-Myers Squibb, Chart Industries, Hyatt Hotels & Progressive
